System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Chii-Min Hwu is an expert in Endocrinology at Taipei Veterans General Hospital (Taiwan). As of October 2026, ScienceLeadR ranks Chii-Min Hwu in the top 1% of experts worldwide for Glucose Metabolism Disorders, Diabetes Mellitus and Epidemiologic Studies. Chii-Min Hwu has authored 301 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 2 of them ongoing. SLR score: 1,039 (community average: 125). How the SLR is computed.

LeadR Profile

Chii-Min Hwu Taipei Veterans General Hospital Taiwan
1 039 ScienceLeadR Reputation 1039

Unlock

Register Login
Network Map

Endocrinology

Subspecialties: Public Health - Genetics - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1995 - 2026
Source: PubMed

Taipei Veterans General Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 301

Citations

Citations: 7 153 1st author: 22 Last author: 77 Unique author: 3

Main journals

J Chin Med Assoc 16
Diabetes Res Clin Pract 12
J Diabetes Investig 11
Nat Commun 9
Nature 8

Best Journals

Nature 8
Nat Genet 5
Science 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Comparative Neoplasm Risk of Mirabegron and Antimuscarinic Therapy in Overactive Bladder: A Multicenter Target Trial Emulation.
PMID 42938816 — urinary bladder, mortality, neoplasms, muscarinic antagonists, obesity, therapeutics, urinary bladder, overactive		Cancers (Basel)20260
Local ancestry-aware genome-wide meta-analysis uncovers novel genetic loci for sickle cell disease nephropathy.
PMID 42616615 — cells, genes, anemia, sickle cell, genome, genetic loci, kidney, hematologic diseases		Blood Adv20261
Sudomotor dysfunction is associated with loss of residual renal function in patients undergoing peritoneal dialysis.
PMID 42800730 — creatinine, peritoneal dialysis, foot, accounting, negotiating		J Formos Med Assoc20260
Association Between Thiazolidinedione Therapy and Tuberculosis-Related Events in Type 2 Diabetes: A Population-Based Cohort Study.
PMID 42795560 — diabetes mellitus, hospitalization, cohort studies, pioglitazone, tuberculosis, therapeutics, rosiglitazone, diabetes mellitus, type 2		Microorganisms20260
Findings Interpretation Concerns Regarding the Emulated Target Trial of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Psoriatic Arthritis [Response to Letter].
PMID 42757044 — glucagon-like peptide 1, sodium-glucose transporter 2 inhibitors, arthritis, psoriatic, glucagon-like peptide-1 receptor, arthritis, drug therapy		Drug Des Devel Ther20260

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 10

By phase:

N/A 10
Phase 3 4
Phase 4 1

By status:

Completed 9
Unknown 4
Recruiting 2

By type:

Observational 8
Interventional 7

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 1
multicentric5to9 0
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190 — diabetes mellitus, receptors, islet amyloid polypeptide, safety, amylin receptor agonists, obesity, incretins, overweight, islet amyloid polypeptide, diabetes mellitus, type 2		Phase 3Recruiting2026
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07282600 — diabetes mellitus, safety, obesity, overweight, diabetes mellitus, type 2		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS